Conversion surgery after atezolizumab plus bevacizumab therapy for postoperative pulmonary metastasis of hepatocellular carcinoma complicated by polymyalgia rheumatica as an immune-related adverse event
Clinical Journal of Gastroenterology · 26.10.2026
DOI: 10.1007/s12328-026-02472-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Journal of Gastroenterology, online erschienen am 26.10.2026. Verfasst von Takashi Homma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Kawasaki Saiwai Hospital, 31-27 Omiyacho, Saiwai-ku, Kawasaki, Kanagawa, 212-0014, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Atezolizumab plus bevacizumab has become a standard first-line therapy for unresectable hepatocellular carcinoma (HCC). However, immune-related adverse events (irAEs), including rare rheumatologic manifestations, may complicate treatment continuation. A 75-year-old woman underwent left hepatectomy with gastric transection and repair for a giant HCC. Eight months postoperatively, computed tomography revealed small nodules in the right upper and middle lung lobes suspicious for metastases. Sorafenib was initiated but discontinued 10 days later because of a severe skin rash, and atezolizumab plus bevacizumab therapy was subsequently initiated. The upper lobe lesion disappeared and the middle lobe lesion remained stable. After 20 treatment courses, the patient developed fever and severe generalized pain, leading to treatment interruption. She was diagnosed with polymyalgia rheumatica as an irAE and promptly improved with prednisolone therapy, allowing resumption of immunotherapy. Subsequently, the right middle lobe lesion gradually enlarged without evidence of other recurrence. Thoracoscopic right middle lobectomy was therefore performed, and histopathology confirmed pulmonary metastasis from HCC. The patient remains recurrence-free 2 years and 9 months after pulmonary resection with no relapse of polymyalgia rheumatica on low-dose corticosteroids. This case demonstrates that appropriate management of irAEs can allow continuation of immunotherapy and enable conversion surgery for pulmonary metastasis of HCC, resulting in a favorable long-term outcome.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Kawasaki Saiwai Hospital, 31-27 Omiyacho, Saiwai-ku, Kawasaki, Kanagawa, 212-0014, Japan.
- Department of Surgery, Kawasaki Saiwai Hospital, 31-27 Omiyacho, Saiwai-ku, Kawasaki, Kanagawa, 212-0014, Japan. y-hara@saiwaihp.jp.
- Department of General Thoracic Surgery, Kawasaki Saiwai Hospital, Kawasaki, Japan.
Zitieren
APA
Homma, T., Hara, Y., Watanabe, K., Mochizuki, I., Suenaga, Y., Amiki, M., Nagayama, K., Narita, K., Goto, M., & Tachimori, Y. (2026). Conversion surgery after atezolizumab plus bevacizumab therapy for postoperative pulmonary metastasis of hepatocellular carcinoma complicated by polymyalgia rheumatica as an immune-related adverse event. Clinical Journal of Gastroenterology. https://doi.org/10.1007/s12328-026-02472-4
Vancouver
Homma T, Hara Y, Watanabe K, Mochizuki I, Suenaga Y, Amiki M, et al. Conversion surgery after atezolizumab plus bevacizumab therapy for postoperative pulmonary metastasis of hepatocellular carcinoma complicated by polymyalgia rheumatica as an immune-related adverse event. Clinical Journal of Gastroenterology. 2026. doi:10.1007/s12328-026-02472-4
BibTeX
@article{Homma2026,
author = {Homma, Takashi and Hara, Yoshiaki and Watanabe, Kazuharu and Mochizuki, Ichitaro and Suenaga, Yasuhito and Amiki, Manabu and Nagayama, Kazuhiro and Narita, Kazuhiro and Goto, Manabu and Tachimori, Yuji},
title = {Conversion surgery after atezolizumab plus bevacizumab therapy for postoperative pulmonary metastasis of hepatocellular carcinoma complicated by polymyalgia rheumatica as an immune-related adverse event},
journal = {Clinical Journal of Gastroenterology},
year = {2026},
doi = {10.1007/s12328-026-02472-4}
}
EUVIMED